News | March 17, 2024
Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr
Both organisations enter into a long- term collaboration to expand patient access in India
Both organisations enter into a long- term collaboration to expand patient access in India
The drug will target specific genetic mutations prevalent in certain types of cancers
The Convocation ceremony was organized for students skilled and certified in Ayush
Dr Sheth's will commission a Healthmobile on Wheels initiative to ensure that healthcare doesn't remain confined to urban centers
This agreement paves the way for the introduction of YESAFILI into the Canadian market
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Academic and Policy Research to get further boost, RIS will bring forth Ayush Service Sector report soon
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
Subscribe To Our Newsletter & Stay Updated
